DNA methylation markers predict recurrence-free interval in triple-negative breast cancer

Mary Jo Fackler, Soonweng Cho, Leslie Cope, Edward Gabrielson, Kala Visvanathan, Kathleen Wilsbach, Danielle Meir-Levi, Charles F. Lynch, Jeffrey Marks, Joseph Geradts, Meredith M. Regan, Giuseppe Viale, Antonio C. Wolff, Saraswati Sukumar, Christopher B. Umbricht

Research output: Contribution to journalArticlepeer-review

Abstract

We lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecular tools to predict disease recurrence. Methylation array analysis was performed on 110 samples treated by locoregional therapy obtained from institutional cohorts. Discovered marker sets were then tested by Kaplan−Meier analyses in a prospectively collected TNBC cohort of 49 samples from the no-chemotherapy arms of IBCSG trials VIII and IX, and by logistic regression in a chemotherapy-treated cohort of 121 TNBCs from combined IBCSG trials and institutional repositories. High methylation was associated with shorter recurrence-free interval in the no-chemotherapy arm of the IBCSG studies, as well as in the chemotherapy-treated patients within the combined institutional and IBCSG chemotherapy cohorts (100 marker panel, p = 0.002; 30 marker panel, p = 0.05). Chromosome 19 sites were enriched among these loci. In conclusion, our hypermethylation signatures identify increased recurrence risk independent of whether patients receive chemotherapy.

Original languageEnglish (US)
Article number3
Journalnpj Breast Cancer
Volume6
Issue number1
DOIs
StatePublished - Dec 1 2020

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'DNA methylation markers predict recurrence-free interval in triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this